Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
444 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01332656 | Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel(OPSALIN) | completed | Phase 2 | 154 | SanofiINDUSTRY | 10 | Dec 21, 2015 | clinicaltrials |
| NCT01293630 | A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | SanofiINDUSTRY | 1 | Oct 30, 2015 | clinicaltrials |
| NCT02061631 | Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck(DECIDE) | completed | Phase 2 | 35 | SanofiINDUSTRY | 1 | Oct 8, 2015 | clinicaltrials |
| NCT01362985 | Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor | completed | — | 201 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 13, 2015 | clinicaltrials |
| NCT02221479 | Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma | completed | Phase 2 | 14 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 4, 2015 | clinicaltrials |
| NCT00565448 | Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents | completed | Phase 2 | 75 | SanofiINDUSTRY | 14 | Jul 30, 2015 | clinicaltrials |
| NCT01140607 | Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment | completed | Phase 1 | 56 | SanofiINDUSTRY | 1 | Jul 21, 2015 | clinicaltrials |
| NCT00046696 | A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors. | completed | Phase 1 | 32 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 20, 2015 | clinicaltrials |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | terminated | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 1, 2015 | clinicaltrials |
| NCT00923182 | A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 1 | 6 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00991133 | A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 | 8 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00081900 | A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care | terminated | Phase 1 / Phase 2 | 38 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 13, 2015 | clinicaltrials |
| NCT01500720 | Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer | completed | Phase 2 | 179 | SanofiINDUSTRY | 16 | Apr 13, 2015 | clinicaltrials |
| NCT01673737 | A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer | completed | Phase 1 | 75 | SanofiINDUSTRY | 2 | Apr 10, 2015 | clinicaltrials |
| NCT00924443 | A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable | completed | Phase 2 | 69 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Apr 1, 2015 | clinicaltrials |
| NCT00077961 | Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL | terminated | Phase 1 / Phase 2 | 49 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 26, 2015 | clinicaltrials |
| NCT00741780 | Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662). | completed | — | 164 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Mar 24, 2015 | clinicaltrials |
| NCT00838357 | A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).(PREDICT) | completed | Phase 3 | 118 | Genzyme, a Sanofi CompanyINDUSTRY | 7 | Mar 24, 2015 | clinicaltrials |
| NCT00990054 | Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 24, 2015 | clinicaltrials |
| NCT01736163 | A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours | completed | — | 144 | Genzyme, a Sanofi CompanyINDUSTRY | 4 | Mar 23, 2015 | clinicaltrials |
| NCT01738373 | Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation | completed | — | 262 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 23, 2015 | clinicaltrials |
| NCT00694590 | Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 20, 2015 | clinicaltrials |
| NCT00088543 | Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant | completed | N/A | 60 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Mar 18, 2015 | clinicaltrials |
| NCT00196729 | Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration | completed | Phase 3 | 63 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Mar 18, 2015 | clinicaltrials |
| NCT00295763 | A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. | completed | Phase 3 | 61 | Genzyme, a Sanofi CompanyINDUSTRY | 5 | Mar 18, 2015 | clinicaltrials |
| NCT00042354 | Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00050323 | Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00051701 | Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 61 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00068211 | Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00078455 | Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00082134 | Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT01254279 | Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen | completed | Phase 3 | 984 | SanofiINDUSTRY | 29 | Jan 21, 2015 | clinicaltrials |
| NCT01324583 | Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer | completed | Phase 1 | 48 | SanofiINDUSTRY | 1 | Jan 7, 2015 | clinicaltrials |
| NCT01930552 | A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies | completed | Phase 1 | 20 | SanofiINDUSTRY | 1 | Jan 7, 2015 | clinicaltrials |
| NCT01767714 | Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation | completed | Phase 3 | 100 | SanofiINDUSTRY | 1 | Dec 9, 2014 | clinicaltrials |
| NCT01193595 | Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 39 | SanofiINDUSTRY | 3 | Dec 3, 2014 | clinicaltrials |
| NCT01392924 | Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors | completed | Phase 1 | 10 | SanofiINDUSTRY | 1 | Dec 3, 2014 | clinicaltrials |
| NCT02085005 | Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer(Drop and Go) | withdrawn | Phase 2 | 0 | SanofiINDUSTRY | 0 | Nov 18, 2014 | clinicaltrials |
| NCT01470456 | Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 50 | SanofiINDUSTRY | 3 | Nov 13, 2014 | clinicaltrials |
| NCT01497964 | Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy(GASTANA) | completed | Phase 1 / Phase 2 | 16 | SanofiINDUSTRY | 1 | Nov 10, 2014 | clinicaltrials |
| NCT00343239 | Docetaxel in Locally Advanced Gastric Adenocarcinoma(NEOTAX) | completed | Phase 2 | 59 | SanofiINDUSTRY | 1 | Nov 4, 2014 | clinicaltrials |
| NCT01121848 | Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer | completed | Phase 3 | 108 | SanofiINDUSTRY | 1 | Oct 27, 2014 | clinicaltrials |
| NCT01455532 | A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors | completed | Phase 1 | 59 | SanofiINDUSTRY | 1 | Oct 22, 2014 | clinicaltrials |
| NCT00968916 | Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors | completed | Phase 1 | 15 | SanofiINDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT01436565 | A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers | completed | Phase 1 | 26 | SanofiINDUSTRY | 1 | Jun 13, 2014 | clinicaltrials |
| NCT00607152 | Rasburicase (Fasturtec) Registration Trial | terminated | Phase 3 | 10 | SanofiINDUSTRY | 1 | May 8, 2014 | clinicaltrials |
| NCT00315705 | A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. | completed | Phase 1 / Phase 2 | 50 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 14, 2014 | clinicaltrials |
| NCT00317642 | A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) | completed | Phase 3 | 326 | Genzyme, a Sanofi CompanyINDUSTRY | 5 | Apr 14, 2014 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials